Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study

• Published in: Advances in therapy Vol. 41; no. 1; pp. 315 - 330
• Main Authors: Schmalzing, Marc, Kellner, Herbert, Askari, Ayman, De Toro Santos, Javier, Vazquez Perez-Coleman, Julio Cesar, Foti, Rosario, Jeka, Sławomir, Haraoui, Boulos, Allanore, Yannick, Peichl, Peter, Oehri, Martin, Rahman, Masiur, Furlan, Fabricio, Romero, Elisa, Hachaichi, Sohaib, Both, Charlotte, Brueckmann, Ines, Sheeran, Tom
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 2024
• Subjects: Antirheumatic Agents - adverse effects; Arthritis, Psoriatic - drug therapy; Arthritis, Rheumatoid - drug therapy; Axial Spondyloarthritis; Biosimilar Pharmaceuticals - adverse effects; Cardiology; Endocrinology; Etanercept - adverse effects; Humans; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Rheumatic Diseases - drug therapy; Rheumatology; Treatment Outcome; Persistence; COMPACT; Effectiveness; SDZ ETN; Real-world; Rheumatic diseases; Non-interventional; Safety; PRO; Biosimilar
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-023-02706-8

Introduction COMPACT, a non-interventional study, evaluated the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis (axSpA) or psoriatic arthritis (PsA) treated with SDZ ETN (etanercept [ETN] biosimilar) in Europe and Canada. Methods Patients (aged ≥ 18 years) who have been treated with SDZ ETN were categorised on the basis of prior treatment status (groups A–D): patients in clinical remission or with low disease activity under treatment with reference ETN or biosimilar ETN and switched to SDZ ETN; patients who received non-ETN targeted therapies and switched to SDZ ETN; biologic-naïve patients who started SDZ ETN after conventional therapy failure; or disease-modifying anti-rheumatic drug (DMARD)-naïve patients with RA considered suitable for treatment initiation with a biologic and started on treatment with SDZ ETN. The primary endpoint was drug persistence, defined as time from study enrolment until discontinuation of SDZ ETN treatment. Results Of the 1466 patients recruited, 844 (57.6%) had RA, 334 (22.8%) had axSpA and 288 (19.6%) had PsA. Patients had an ongoing SDZ ETN treatment at the time of enrolment for an observed average of 138 days (range 1–841); 22.7% of patients discontinued SDZ ETN through 12 months of study observation. Overall, all the patients receiving SDZ ETN showed good treatment persistence at 12 months with discontinuation rates of 15.2%, 25.7% and 27.8% in groups A, B and C, respectively. Across all patient groups, no major differences were observed in the disease activity and PRO scores between baseline and month 12. Injection-site reactions were low across the treatment groups. Conclusion These results support the effectiveness and safety of SDZ ETN treatment in patients with RA, axSpA or PsA in real-life conditions. The treatment persistence rates observed were consistent with previously published reports of patients treated with reference or other biosimilar ETN. No new safety signals were identified.